Supplementary funding to support the extension of the EDCTP-funded PrEPVacc trial

“补充资金，以支持扩展EDCTP资助的试验““在非洲的两种DNA-MVA-或DNA-Env蛋白HIV-1疫苗方案与暴露前预防（PrEPVacc）的联合疗效研究"”，由Jonathan Weber教授（英国帝国理工学院）主持。PrEPVacc是一项IIb期、三臂、两阶段的HIV疫苗有效性试验，第二次随机化是为了将较新的PrEP药物Descovy与PrEP的既定标准Truvada进行比较（https：//www.prepvacc.org/）补充资金将允许对试验参与者进行随访并对试验数据进行完整分析。"

"Supplementary funding to support the extension of the EDCTP-funded trial ""A combination efficacy study in Africa of two DNA-MVA- or DNA- Env protein HIV-1 vaccine regimens with pre-exposure prophylaxis (PrEPVacc)"" held by Professor Jonathan Weber (Imperial College of Science Technology and Medicine, UK). PrEPVacc is a Phase IIb, three-arm, two-stage HIV efficacy vaccine trial with a second randomisation to compare the newer PrEP drug Descovy to the established standard for PrEP, Truvada (https://www.prepvacc.org/)The supplementary funding will allow follow-up of trial participants and complete analysis of the trial data. "